Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms
Authors
Keywords
-
Journal
Microorganisms
Volume 7, Issue 8, Pages 270
Publisher
MDPI AG
Online
2019-08-19
DOI
10.3390/microorganisms7080270
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Omadacycline for Community-Acquired Bacterial Pneumonia
- (2019) Roman Stets et al. NEW ENGLAND JOURNAL OF MEDICINE
- Omadacycline for Acute Bacterial Skin and Skin-Structure Infections
- (2019) William O’Riordan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft tissue infections
- (2019) Edit Urbán et al. CLINICAL MICROBIOLOGY AND INFECTION
- Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
- (2019) Keith A Rodvold et al. CLINICAL INFECTIOUS DISEASES
- Ceftaroline Efficacy and Safety in Treatment of Complicated Skin and Soft Tissue Infection: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
- (2019) Shao-Huan Lan et al. Journal of Clinical Medicine
- Ozenoxacin: A Novel Topical Quinolone for Impetigo
- (2018) Christopher Wren et al. ANNALS OF PHARMACOTHERAPY
- Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs
- (2018) Jorge Ignacio González Borroto et al. Future Microbiology
- Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo
- (2018) Theodore Rosen et al. JAMA Dermatology
- Infections by multidrug-resistant Gram-negative Bacteria: what's new in our arsenal and what's in the pipeline?
- (2018) Despoina Koulenti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Attributable Mortality of Healthcare-Associated Infections Due to Multidrug-Resistant Gram-Negative Bacteria and Methicillin-Resistant Staphylococcus Aureus
- (2017) Richard E. Nelson et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new
- (2017) Michael Z. David et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
- (2017) Randall K. Hoover et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
- (2017) Christine M. Sanfilippo et al. Drugs in research & development
- A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study)
- (2017) Roman Stets et al. Open Forum Infectious Diseases
- Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials
- (2017) Thomas P. Lodise et al. Open Forum Infectious Diseases
- Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects
- (2016) Todd A. Riccobene et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections
- (2016) Stephen Villano et al. Future Microbiology
- Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens
- (2016) Abrar K. Thabit et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- High incidence of neutropenia in patients with prolonged ceftaroline exposure
- (2016) Kari J. Furtek et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities
- (2016) Matthew Dryden et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them
- (2016) Bahman Khameneh et al. MICROBIAL PATHOGENESIS
- Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections
- (2016) Olivia Ferrández et al. Drug Design Development and Therapy
- Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline
- (2015) Laura Honeyman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ReducedIn VitroActivity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia
- (2015) I. J. Abbott et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program
- (2015) Douglas J. Biedenbach et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program
- (2015) Douglas J. Biedenbach et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics of Ceftaroline in Normal Body Weight and Obese (Classes I, II, and III) Healthy Adult Subjects
- (2015) Julie Ann Justo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Oritavancin: A Long-Half-Life Lipoglycopeptide
- (2015) Louis D. Saravolatz et al. CLINICAL INFECTIOUS DISEASES
- A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
- (2015) Michael W. Dunne et al. CLINICAL INFECTIOUS DISEASES
- Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic
- (2015) Steven D. Burdette et al. CLINICAL INFECTIOUS DISEASES
- Beyond Vancomycin: The Tail of the Lipoglycopeptides
- (2015) Kenneth P. Klinker et al. CLINICAL THERAPEUTICS
- Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe
- (2015) Daniel F. Sahm et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens
- (2015) George G. Zhanel et al. DRUGS
- Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones
- (2015) Antonios Douros et al. Expert Opinion on Drug Metabolism & Toxicology
- Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia
- (2015) Thomas WL Scheeren Future Microbiology
- Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy
- (2015) Françoise Van Bambeke Future Microbiology
- A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections
- (2015) William O’Riordan et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Evaluation of tedizolid againstStaphylococcus aureusand enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid
- (2015) Katie E. Barber et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA
- (2015) Frieder Schaumburg et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin
- (2015) Jeff Kingsley et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Development of novel antibacterial drugs to combat multiple resistant organisms
- (2015) Matteo Bassetti et al. LANGENBECKS ARCHIVES OF SURGERY
- High prevalence of multi-drug resistant Streptococcus pneumoniae among healthy children in Thailand
- (2015) Rapee Thummeepak et al. Journal of Infection and Public Health
- Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival
- (2014) G. Ralph Corey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study
- (2014) G. Ralph Corey et al. CLINICAL INFECTIOUS DISEASES
- A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia
- (2014) S. S. Awad et al. CLINICAL INFECTIOUS DISEASES
- Mechanisms of antibiotic resistance in enterococci
- (2014) William R Miller et al. Expert Review of Anti-Infective Therapy
- In vitro antimicrobial activity of the novel oxazolidinone tedizolid and comparator agents against Staphylococcus aureus and linezolid-resistant Gram-positive pathogens: a multicentre study in China
- (2014) Hongbin Chen et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial
- (2014) Gregory J Moran et al. LANCET INFECTIOUS DISEASES
- Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections
- (2014) G. Ralph Corey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
- (2014) Helen W. Boucher et al. NEW ENGLAND JOURNAL OF MEDICINE
- High Incidence of Discontinuations Due to Adverse Events in Patients Treated with Ceftaroline
- (2014) Rupali Jain et al. PHARMACOTHERAPY
- Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline
- (2013) Michael P. Draper et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections
- (2013) Philippe Prokocimer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Which antibiotic for resistant Gram-positives, and why?
- (2013) John S. Bradley JOURNAL OF INFECTION
- Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers
- (2012) Seth T. Housman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure Infections
- (2012) Gary J. Noel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance
- (2012) Andrew A. Udy et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation
- (2012) Susan C. Nicholson et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization
- (2012) J. M. Remy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In VivoPharmacodynamics of Torezolid Phosphate (TR-701), a New Oxazolidinone Antibiotic, against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Strains in a Mouse Thigh Infection Model
- (2011) Arnold Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Topoisomerase Mutations That Are Associated with High-Level Resistance to Earlier Fluoroquinolones in Staphylococcus aureus Have Less Effect on the Antibacterial Activity of Besifloxacin
- (2011) Christine M. Sanfilippo et al. CHEMOTHERAPY
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Efficacy and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% Administered Twice Daily for 3 Days in the Treatment of Bacterial Conjunctivitis: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study in Adults and Children
- (2011) Bruce E. Silverstein et al. CLINICAL THERAPEUTICS
- Ceftaroline: a comprehensive update
- (2011) Darpan Kaushik et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride
- (2011) W. Haas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Affinity of Ceftaroline and Other -Lactams for Penicillin-Binding Proteins from Staphylococcus aureus and Streptococcus pneumoniae
- (2010) K. Kosowska-Shick et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing
- (2010) A. Belley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia
- (2010) Thomas M. File et al. CLINICAL INFECTIOUS DISEASES
- Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
- (2010) E. Rubinstein et al. CLINICAL INFECTIOUS DISEASES
- Community-Associated Methicillin-Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic
- (2010) M. Z. David et al. CLINICAL MICROBIOLOGY REVIEWS
- Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae
- (2010) Wolfgang Haas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity
- (2010) D. Biek et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae
- (2010) H. Moisan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections
- (2010) M. L. Corrado JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria
- (2009) W. Haas et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole
- (2009) K. A. Rodvold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II
- (2009) C. S. Lunde et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates
- (2009) F. F. Arhin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibiotic resistance—What’s dosing got to do with it?
- (2009) Jason A. Roberts et al. CRITICAL CARE MEDICINE
- Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli
- (2009) E. Cambau et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment
- (2009) Thomas Marbury et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures
- (2008) Samuel E. Wilson et al. AMERICAN JOURNAL OF SURGERY
- Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms
- (2008) Martin E. Stryjewski et al. CLINICAL INFECTIOUS DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started